SCHEMBL1343116

SCHEMBL1343116

COc1cccc2c(-c3c(S)n[nH]c3-c3cc(C(C)C)c(O)cc3O)cccc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSP90AA1 P07900 8/20 0.38
▸ HSP90AB1 P08238 6/20 0.37
▸ G6PD P11413 1/20 0.35
▸ MEN1 O00255 3/20 0.34
▸ KMT2A Q03164 3/20 0.34
▸ SIRT5 Q9NXA8 1/20 0.34
▸ TP53 P04637 2/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ CCNE2 O96020 1/20 0.34
▸ CDK4 P11802 1/20 0.34
▸ CCND1 P24385 1/20 0.34
▸ CCNE1 P24864 1/20 0.34
▸ CDK2 P24941 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ ALOX12 P18054 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14286503 0.94 HSP90AA1 (0.40) HSP90AA1HSP90AB1MEN1KMT2ASIRT5
SCHEMBL16541252 0.89 HSP90AA1 (0.39) HSP90AA1HSP90AB1G6PDMEN1KMT2A
SCHEMBL13677641 0.84 HSP90AA1 (0.37) HSP90AA1HSP90AB1MEN1KMT2AALDH1A1
SCHEMBL1147962 0.82 HSP90AA1 (0.40) HSP90AA1HSP90AB1TP53ALDH1A1HPGD
SCHEMBL1148628 0.77 MEN1 (0.35) MEN1KMT2ATP53ALDH1A1LMNA
SCHEMBL12553712 0.77 HSP90AA1 (0.37) HSP90AA1HSP90AB1TP53LMNAALOX15
SCHEMBL1147799 0.76 HSP90AA1 (0.36) HSP90AA1HSP90AB1
SCHEMBL1147883 0.74 HSP90AA1 (0.37) HSP90AA1HSP90AB1ALDH1A1LMNAALOX12
SCHEMBL1148531 0.73 CHEK1 (0.34) HSP90AA1HSP90AB1ALDH1A1LMNAALOX12
SCHEMBL1148563 0.72 HSP90AA1 (0.38) HSP90AA1HSP90AB1MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190144398-A1 METHOD FOR TREATING INFLAMMATORY DISORDERS SYNTA PHARMACEUTICALS CORP. 2019-05-16 — — US disclosed
US-20170320837-A1 METHOD FOR TREATING INFLAMMATORY DISORDERS SYNTA PHARMACEUTICALS CORP. 2017-11-09 — — US disclosed
US-9108933-B2 Method for treating proliferative disorders associated with mutations in c-Met SYNTA PHARMACEUTICALS CORP. (US) 2015-08-18 — — US disclosed
US-9108933-B2 Method for treating proliferative disorders associated with mutations in c-Met SYNTA PHARMACEUTICALS CORP. (US) 2015-08-18 — — US disclosed
US-9108933-B2 Method for treating proliferative disorders associated with mutations in c-Met SYNTA PHARMACEUTICALS CORP. (US) 2015-08-18 — — US disclosed
US-9101614-B2 Method for treating non-Hodgkin's lymphoma SYNTA PHARMACEUTICALS CORP. (US) 2015-08-11 — — US disclosed
US-9101614-B2 Method for treating non-Hodgkin's lymphoma SYNTA PHARMACEUTICALS CORP. (US) 2015-08-11 — — US disclosed
US-9101614-B2 Method for treating non-Hodgkin's lymphoma SYNTA PHARMACEUTICALS CORP. (US) 2015-08-11 — — US disclosed
US-20150174134-A1 METHOD FOR INHIBITING TOPOISOMERASE II SYNTA PHARMACEUTICALS CORP (US) 2015-06-25 — — US disclosed
US-20150094349-A1 Method for Treating Proliferative Disorders Associated with Protooncogene Products SYNTA PHARMACEUTICALS CORP (US) 2015-04-02 — — US disclosed
US-20100069442-A1 PYRAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY SYNTA PHARMACEUTICALS CORP. 2010-03-18 — — US disclosed
US-7608635-B2 heat shock protein 90 inhibitors; antiproliferative agents; angiogenesis inhibitors SYNTA PHARMACEUTICALS CORP. (US) 2009-10-27 — — US disclosed
US-7608635-B2 heat shock protein 90 inhibitors; antiproliferative agents; angiogenesis inhibitors SYNTA PHARMACEUTICALS CORP. (US) 2009-10-27 — — US disclosed
US-20080004276-A1 Method for treating non-hodgkin's lymphoma LSI FINANCING LLC, AS ADMINISTRATIVE AGENT 2008-01-03 — — US disclosed
US-20080004276-A1 Method for treating non-hodgkin's lymphoma LSI FINANCING LLC, AS ADMINISTRATIVE AGENT 2008-01-03 — — US disclosed
US-20080004276-A1 Method for treating non-hodgkin's lymphoma LSI FINANCING LLC, AS ADMINISTRATIVE AGENT 2008-01-03 — — US disclosed
US-20080004266-A1 Method for treating proliferative disorders associated with protooncogene products LSI FINANCING LLC, AS ADMINISTRATIVE AGENT 2008-01-03 — — US disclosed
US-20070191445-A1 heat shock protein 90 inhibitors; antiproliferative agents; angiogenesis inhibitors LSI FINANCING LLC, AS ADMINISTRATIVE AGENT 2007-08-16 — — US disclosed
US-20070191445-A1 heat shock protein 90 inhibitors; antiproliferative agents; angiogenesis inhibitors LSI FINANCING LLC, AS ADMINISTRATIVE AGENT 2007-08-16 — — US disclosed
WO-2007021966-A1 PYRAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY SYNTA PHARMACEUTICALS CORP. (US) 2007-02-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191445-A1 heat shock protein 90 inhibitors; antiproliferative agents; angiogenesis inhibitors HSP90AB1, HSP90AA1, HSP90AB2P HSP90AA1 2/4885HSP90AB1 1/4885G6PD 1863/4885
US-20150174134-A1 METHOD FOR INHIBITING TOPOISOMERASE II TOP2A, TOP2B, TOP1 HSP90AA1 8/4885HSP90AB1 6/4885G6PD 2173/4885
US-20100069442-A1 PYRAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY HSP90AB1, HSP90AA1, HSP90B1 HSP90AA1 2/4885HSP90AB1 1/4885G6PD 2301/4885
US-20150094349-A1 Method for Treating Proliferative Disorders Associated with Protooncogene Products HSP90AB1, HSP90AB2P, HSP90AA1 HSP90AA1 3/4885HSP90AB1 1/4885G6PD 3418/4885
US-20080004276-A1 Method for treating non-hodgkin's lymphoma HSP90AB1, HSP90AB2P, HSP90B1 HSP90AA1 4/4885HSP90AB1 1/4885G6PD 824/4885
US-20190144398-A1 METHOD FOR TREATING INFLAMMATORY DISORDERS TNF, IL2, IL5 HSP90AA1 531/4885HSP90AB1 605/4885G6PD 556/4885
US-20170320837-A1 METHOD FOR TREATING INFLAMMATORY DISORDERS TNF, IL2, IL5 HSP90AA1 531/4885HSP90AB1 605/4885G6PD 556/4885
US-20080004266-A1 Method for treating proliferative disorders associated with protooncogene products HSP90AB1, HSP90AB2P, HSP90AA1 HSP90AA1 3/4885HSP90AB1 1/4885G6PD 3418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback